Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Two infliximab switching studies have provided reassuring data on the safety of Celltrion’s CT-P13 infliximab biosimilar to treat IBD. While one report explores changing pediatric patients to CT-P13 from the Remicade reference drug, the other looks at reverse switching patients from the biosimilar to the originator brand.
Double-digit rises and falls in the average prices of recently-launched generics recorded by market researcher WaveData demonstrated the volatile pricing dynamics of the UK market in December.
Patients in the UK are being switched to biosimilars without being consulted or receiving the support they need, a report published by the Patients Association and funded by AbbVie has found. The charity is calling for shared decision-making and collaborative working between patients and clinicians.
Healthcare providers in the US and Europe are still cautious about biosimilars due to limited knowledge, low prescribing comfort, and safety and efficacy concerns, according to a review evaluating clinicians’ knowledge, perceptions and prescribing behaviors of such drugs.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.